But if you view the platform for all solid cancers it is probably still cheap even without an RA approval yet. I guess it is how one looks at the product. Sort of like AMZN when it took forever to turn a profit but valued pretty high. I cannot think of a biotech in this situation. I didn’t follow AMGN or the other earth shattering biotechs that early on. Maybe you remember how they traded. Because if it is all solid tumors, I can see $300 minimum in 4 to 5 years.
You do post the best screenshots. Appreciate them.